PRESS

Recent News

2008

Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada

Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada


News Archive

2007

IV Antibiotic CUBICIN Approved for Marketing in Canada Label Includes Both Complicated Skin and Skin Structure and S. Aureus Bloodstream Infections

Oryx Announces Launch of Naprelan™

2006

Oryx Announces Launch of Trosec®

Oryx Announces Launch of Advicor® in Canada

2005

Oryx Announces Launch of Niaspan® in Canada

2003

KOS Pharmaceuticals and Oryx Pharmaceuticals Establish Canadian Commercialization Agreement

Study Published in Journal of the American Medical Association Validates Angiomax® (Bivalirudin) as a New Standard of Care for Angioplasty Treatment

2002

The Medicines Company and Oryx Pharmaceuticals Sign Agreement for Canadian Marketing Rights to Angiomax® (Bivalirudin), a Direct Thrombin Inhibitor for Coronary Angioplasty

Oryx Pharmaceuticals and Novartis Pharmaceuticals Enter Into Agreement For Central Nervous Sytem Products

Oryx Pharmaceuticals and Novartis Pharmaceuticals Canada Introduce A New Treatment For Epilepsy

Oryx Pharmaceuticals Signs Agreement for Corvert®, an Antiarrhythmic for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm

Oryx Announces Launch of FXT 40, the First 40mg Fluoxetine Capsule for the Management of Depression

Oryx Announces Promotion Agreement with Hoffmann-La Roche Limited

Oryx Pharmaceuticals Signs Agreement for PhaSeal®, for Safe Handling of Cytotoxic Drugs